New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer

NCT ID NCT06048133

First seen Jan 31, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tests a combination of four drugs (gemcitabine, cisplatin, zimberelimab, and quemliclustat) as a first treatment for people with advanced bile duct cancer that has not spread beyond the bile ducts. The goal is to see if this mix can slow cancer growth and help people live longer. About 33 adults will take part, receiving the drugs for up to 6 months, then continuing on three of them until the cancer worsens or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Email: •••••@•••••

    Contact

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08903, United States

    Contact

    Contact Email: •••••@•••••

  • University of Michigan Health System

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

    Contact

  • University of Wisconsin

    RECRUITING

    Madison, Wisconsin, 53705, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.